Abdominal manifestations associated with use of a surface-treated AN69 membrane and ACEI during haemodialysis.

1. Adler KR, Lempert N, Scharfman WB. Chronic granulocytic leukemia following successful renal transplantation. Cancer 1978; 41: 2206–2208 2. Koca E, Cetiner D, Goker H et al. Complete cytogenetic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation. Clin Nephrol 2005; 64: 324–325 3. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med 2005; 352: 1049–1050 4. Gottari M, Manzato E, Gherlinzoni F. Imatinib and hyperlipemia. N Engl J Med 2005; 353: 2722–2723 5. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75: 1147–1153 6. Sihvola R, Tikkanen J, Krebs R et al. Platelet-derivated growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation 2003; 75: 334–339